223 related articles for article (PubMed ID: 32017467)
1. Characterization of the immune microenvironment in brain metastases from different solid tumors.
Jiang J; Wu L; Yuan F; Ji J; Lin X; Yang W; Wu J; Shi M; Yang H; Ma Y; Song X; Zhu Z; Zhang H; Zhang J
Cancer Med; 2020 Apr; 9(7):2299-2308. PubMed ID: 32017467
[TBL] [Abstract][Full Text] [Related]
2. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
[TBL] [Abstract][Full Text] [Related]
3. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
4. Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival.
Pocha K; Mock A; Rapp C; Dettling S; Warta R; Geisenberger C; Jungk C; Martins LR; Grabe N; Reuss D; Debus J; von Deimling A; Abdollahi A; Unterberg A; Herold-Mende CC
Clin Cancer Res; 2020 May; 26(9):2231-2243. PubMed ID: 31953311
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
6. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
[TBL] [Abstract][Full Text] [Related]
7. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.
Mansfield AS; Aubry MC; Moser JC; Harrington SM; Dronca RS; Park SS; Dong H
Ann Oncol; 2016 Oct; 27(10):1953-8. PubMed ID: 27502709
[TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
9. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Herrera-Rios D; Mughal SS; Teuber-Hanselmann S; Pierscianek D; Sucker A; Jansen P; Schimming T; Klode J; Reifenberger J; Felsberg J; Keyvani K; Brors B; Sure U; Reifenberger G; Schadendorf D; Helfrich I
Front Immunol; 2020; 11():120. PubMed ID: 32117271
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
Téglási V; Pipek O; Lózsa R; Berta K; Szüts D; Harkó T; Vadász P; Rojkó L; Döme B; Bagó AG; Tímár J; Moldvay J; Szállási Z; Reiniger L
Clin Lung Cancer; 2019 Sep; 20(5):363-369.e2. PubMed ID: 31178388
[TBL] [Abstract][Full Text] [Related]
11. Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.
Takamori S; Takada K; Tagawa T; Toyokawa G; Hirai F; Yamashita N; Okamoto T; Oki E; Yoshizumi T; Oda Y; Maehara Y
Surg Oncol; 2018 Dec; 27(4):637-641. PubMed ID: 30449485
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape.
Song SG; Kim S; Koh J; Yim J; Han B; Kim YA; Jeon YK; Chung DH
Cancer Immunol Immunother; 2021 Jul; 70(7):2035-2048. PubMed ID: 33420630
[TBL] [Abstract][Full Text] [Related]
13. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer.
Kudo Y; Haymaker C; Zhang J; Reuben A; Duose DY; Fujimoto J; Roy-Chowdhuri S; Solis Soto LM; Dejima H; Parra ER; Mino B; Abraham R; Ikeda N; Vaporcyan A; Gibbons D; Zhang J; Lang FF; Luthra R; Lee JJ; Moran C; Huse JT; Kadara H; Wistuba II
Ann Oncol; 2019 Sep; 30(9):1521-1530. PubMed ID: 31282941
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
15. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
[TBL] [Abstract][Full Text] [Related]
16. Tumor immune microenvironment is associated with the growth of intracranial germinomas.
Nishimoto M; Ohara K; Kamamoto D; Tamura R; Miwa T; Yoshida K; Sasaki H
J Neurooncol; 2020 Jan; 146(1):139-146. PubMed ID: 31773448
[TBL] [Abstract][Full Text] [Related]
17. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
18. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
19. Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060).
Li M; Hou X; Sai K; Wu L; Chen J; Zhang B; Wang N; Wu L; Zheng H; Zhang J; Mou Y; Chen L
Oncoimmunology; 2022; 11(1):2059874. PubMed ID: 35402080
[TBL] [Abstract][Full Text] [Related]
20. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
